Limits...
The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines.

Abdel-Latif GA, Al-Abd AM, Tadros MG, Al-Abbasi FA, Khalifa AE, Abdel-Naim AB - Sci Rep (2015)

Bottom Line: Equitoxic combination of herceptin with resveratrol or didox in T47D significantly reduced the IC50 to 0.052 ± 0.001 and 0.0365 ± 0.001 ng/ml, respectively and similar results were obtained in MCF-7.Immunocytochemical staining of HER-2 receptor in T47D cells showed a significant reduction after treatment with herceptin/resveratrol combination compared to herceptin alone.On the contrary, herceptin/didox combination had no significant effect on HER-2 receptor expression.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Egypt.

ABSTRACT
Herceptin is considered an essential treatment option for double negative breast cancer. Resveratrol and didox are known chemopreventive agents with potential anticancer properties. The aim of the current study is to investigate the influence of resveratrol and didox on the cytotoxicity profile of herceptin in HER-2 receptor positive and HER-2 receptor negative breast cancer cell lines (T47D and MCF-7 cell lines, respectively). The IC50's of herceptin in T47D and MCF-7 were 0.133 ± 0.005 ng/ml and 23.3795 ± 1.99 ng/ml respectively. Equitoxic combination of herceptin with resveratrol or didox in T47D significantly reduced the IC50 to 0.052 ± 0.001 and 0.0365 ± 0.001 ng/ml, respectively and similar results were obtained in MCF-7. The gene expression of BCL-xl was markedly decreased in T47D cells following treatment with herceptin/resveratrol compared to herceptin alone. Immunocytochemical staining of HER-2 receptor in T47D cells showed a significant reduction after treatment with herceptin/resveratrol combination compared to herceptin alone. On the contrary, herceptin/didox combination had no significant effect on HER-2 receptor expression. Cell cycle analysis showed an arrest at G2/M phase for both cell lines following all treatments. In conclusion, herceptin/resveratrol and herceptin/didox combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.

No MeSH data available.


Related in: MedlinePlus

Effect of RES and DID on the HER-2 receptor expression in HER treated T47D breast cancer cells.Immunocytochemical staining of HER-2 recptor in T47D was performed and the optical density was measured after treatment with HER (b), RES (c), DID (d), HER + RES (e), HER + DID (f) and compared to control cells (a). Data are expressed as mean ± S.E. (n = 3). Multiple comparisons were performed using one way analysis of variance (ANOVA) followed by LSD as post hoc test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496837&req=5

f3: Effect of RES and DID on the HER-2 receptor expression in HER treated T47D breast cancer cells.Immunocytochemical staining of HER-2 recptor in T47D was performed and the optical density was measured after treatment with HER (b), RES (c), DID (d), HER + RES (e), HER + DID (f) and compared to control cells (a). Data are expressed as mean ± S.E. (n = 3). Multiple comparisons were performed using one way analysis of variance (ANOVA) followed by LSD as post hoc test.

Mentions: To explain the interaction characteristics of herceptin with resveratrol or didox, the expression of HER-2 receptor was determined by measuring the optical density after immunocytochemical staining of the receptor. The expression of HER-2 receptor was significantly decreased after all single and combination treatments compared to the untreated cells (Fig. 3). Combination of herceptin with resveratrol showed a marked reduction of the HER-2 receptor expression compared to single treatments (Fig. 3b,e & g) while combination of herceptin with didox produced no apparent change in the expression of HER-2 receptor (Fig. 3b,f & g).


The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines.

Abdel-Latif GA, Al-Abd AM, Tadros MG, Al-Abbasi FA, Khalifa AE, Abdel-Naim AB - Sci Rep (2015)

Effect of RES and DID on the HER-2 receptor expression in HER treated T47D breast cancer cells.Immunocytochemical staining of HER-2 recptor in T47D was performed and the optical density was measured after treatment with HER (b), RES (c), DID (d), HER + RES (e), HER + DID (f) and compared to control cells (a). Data are expressed as mean ± S.E. (n = 3). Multiple comparisons were performed using one way analysis of variance (ANOVA) followed by LSD as post hoc test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496837&req=5

f3: Effect of RES and DID on the HER-2 receptor expression in HER treated T47D breast cancer cells.Immunocytochemical staining of HER-2 recptor in T47D was performed and the optical density was measured after treatment with HER (b), RES (c), DID (d), HER + RES (e), HER + DID (f) and compared to control cells (a). Data are expressed as mean ± S.E. (n = 3). Multiple comparisons were performed using one way analysis of variance (ANOVA) followed by LSD as post hoc test.
Mentions: To explain the interaction characteristics of herceptin with resveratrol or didox, the expression of HER-2 receptor was determined by measuring the optical density after immunocytochemical staining of the receptor. The expression of HER-2 receptor was significantly decreased after all single and combination treatments compared to the untreated cells (Fig. 3). Combination of herceptin with resveratrol showed a marked reduction of the HER-2 receptor expression compared to single treatments (Fig. 3b,e & g) while combination of herceptin with didox produced no apparent change in the expression of HER-2 receptor (Fig. 3b,f & g).

Bottom Line: Equitoxic combination of herceptin with resveratrol or didox in T47D significantly reduced the IC50 to 0.052 ± 0.001 and 0.0365 ± 0.001 ng/ml, respectively and similar results were obtained in MCF-7.Immunocytochemical staining of HER-2 receptor in T47D cells showed a significant reduction after treatment with herceptin/resveratrol combination compared to herceptin alone.On the contrary, herceptin/didox combination had no significant effect on HER-2 receptor expression.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Egypt.

ABSTRACT
Herceptin is considered an essential treatment option for double negative breast cancer. Resveratrol and didox are known chemopreventive agents with potential anticancer properties. The aim of the current study is to investigate the influence of resveratrol and didox on the cytotoxicity profile of herceptin in HER-2 receptor positive and HER-2 receptor negative breast cancer cell lines (T47D and MCF-7 cell lines, respectively). The IC50's of herceptin in T47D and MCF-7 were 0.133 ± 0.005 ng/ml and 23.3795 ± 1.99 ng/ml respectively. Equitoxic combination of herceptin with resveratrol or didox in T47D significantly reduced the IC50 to 0.052 ± 0.001 and 0.0365 ± 0.001 ng/ml, respectively and similar results were obtained in MCF-7. The gene expression of BCL-xl was markedly decreased in T47D cells following treatment with herceptin/resveratrol compared to herceptin alone. Immunocytochemical staining of HER-2 receptor in T47D cells showed a significant reduction after treatment with herceptin/resveratrol combination compared to herceptin alone. On the contrary, herceptin/didox combination had no significant effect on HER-2 receptor expression. Cell cycle analysis showed an arrest at G2/M phase for both cell lines following all treatments. In conclusion, herceptin/resveratrol and herceptin/didox combinations improved the cytotoxic profile of herceptin in both T47D and MCF-7 breast cancer cell lines.

No MeSH data available.


Related in: MedlinePlus